Finasteride-loaded biodegradable nanoparticles: Near-infrared quantification of plasma and prostate levels

• Published in: Journal of bioactive and compatible polymers 2017-11, Vol.32 (6), p.557-567
• Main Authors: Ahmed, Osama AA, Fahmy, Usama A, Al-Ghamdi, Ahmed S, Aljaeid, Bader M, Aldawsari, Hibah, Fahmy, Omar, Sarhan, Hatem A, Khairul Asri, Mohd G
• Format: Article
• Language: English
• ISSN: 0883-9115; 1530-8030
• DOI: 10.1177/0883911517694397

Finasteride is an orally active testosterone 5-alpha-reductase inhibitor that is used for the treatment of benign prostatic hyperplasia as a surgical alternative. The aim of this work was to improve finasteride levels in plasma and prostate through the formulation of biodegradable finasteride nanoparticles and to quantify finasteride levels using near-infrared application. Finasteride nanoparticles were prepared by emulsion solvent evaporation method utilizing the biodegradable polymers poly(lactic-co-glycolic acid) and poly-ϵ-caprolactone. The prepared nanoparticles were characterized by particle size, zeta potential, and encapsulation efficiency. The selected finasteride-biodegradable formula was examined in vivo, and both plasma and prostate levels of finasteride were quantified utilizing near-infrared technique. Results revealed that the prepared finasteride nanoparticles size range was from 231 ± 78 to 956 ± 224 nm with finasteride–poly-ϵ-caprolactone nanoparticles showing larger particle sizes compared with finasteride–poly(lactic-co-glycolic acid) nanoparticles. The encapsulation efficiency ranged from 68.89% ± 2.99% to 99.15% ± 4.32%. The selected formula of finasteride nanoparticles showed improved levels of finasteride in both plasma and prostate of the investigated rats. The realization of sustained release of biodegradable finasteride nanoparticles for possible oral or parenteral application could improve the activity of the drug for sustaining release time with lower dosing recurrence that improves patient compliance.